N-[4-[(3-bromo-phenyl)amino]quinazolin-6-yl]-(E)-4-(3-(N,N-dimethylamino)propoxy)-4-oxobut-2-enamide | 198960-31-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-[4-[(3-bromo-phenyl)amino]quinazolin-6-yl]-(E)-4-(3-(N,N-dimethylamino)propoxy)-4-oxobut-2-enamide
• 英文别名: 6-Substituted 4-Anilinoquinazoline 24；3-(dimethylamino)propyl (E)-4-[[4-(3-bromoanilino)quinazolin-6-yl]amino]-4-oxobut-2-enoate
• CAS: 198960-31-5
• 化学式: C₂₃H₂₄BrN₅O₃
• 分子量: 498.379
• InChiKey: BBIKEXVBWCYZFP-MDZDMXLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  96.4
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-[4-[(3-bromo-phenyl)amino]quinazolin-6-yl]-(E)-4-(3-(N,N-dimethylamino)propoxy)-4-oxobut-2-enamide 在 三氟乙酸 作用下， 以 水 、 溶剂黄146 、 乙腈 为溶剂， 反应 1.0h， 以12%的产率得到3-(dimethylamino)propyl (2E)-4-{[4-(3-bromoanilino)-6-quinazolinyl]amino}-4-oxo-2-butenoate tristrifluoroacetic acid salt
  参考文献：
  名称：

  Irreversible inhibitors of tyrosine kinases

  摘要：

  本发明提供了一种不可逆抑制酪氨酸激酶的化合物。还提供了一种治疗癌症、再狭窄、动脉粥样硬化、子宫内膜异位症和牛皮癣的方法，以及包含一种不可逆抑制酪氨酸激酶的化合物的药物组合物。

  公开号：

  US06344459B1
• 作为产物：
  描述：

  N4-(3-溴苯基)喹唑啉-4,6-二胺 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 N-[4-[(3-bromo-phenyl)amino]quinazolin-6-yl]-(E)-4-(3-(N,N-dimethylamino)propoxy)-4-oxobut-2-enamide
  参考文献：
  名称：

  Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor

  摘要：

  4-Anilinoquinazoline- and 4-anilinopyrido[3,4-d]pyrimidine-6-acrylamides are potent pan-erbB tyrosine kinase inactivators, and one example (CI-1033) is in clinical trial. A series of analogues with a variety of Michael acceptor units at the 6-position were prepared to define the structural requirements for irreversible inhibition. A particular goal was to determine whether additional functions to increase solubility could be appended to the Michael acceptor. Substituted acrylamides were prepared by direct acylation of the corresponding 6-amines with the requisite acid or acid chloride. Vinylsulfonamide derivatives were obtained by acylation of the amines with chloroethylsulfonyl chloride followed by base-promoted elimination. Vinylsulfone and vinylsulfine derivatives were prepared by oxidation and base elimination of a hydroxyethylthio intermediate. The compounds were evaluated for their inhibition of phosphorylation of the isolated EGFR enzyme and for inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells and of heregulin-stimulated autophosphorylation of erbB2 in MDA-MB 453 cells. Substitution at the nitrogen of the acrylamide was tolerated only with a methyl group; larger substituents were dystherapeutic, and no substitution at all was tolerated at the acrylamide ex-carbon. In contrast, while electron-donating groups at the acrylamide P-carbon were not useful, even quite large electron-withdrawing groups (which increase its electrophilicity) were tolerated. A series of derivatives with solubility-enhancing substituents linked to the acrylamide P-carbon via amides were potent irreversible inhibitors of isolated EGFR (IC(50)s = 0.4-1.1 nM), with weakly basic morpholine and imidazole derivatives being the best. Vinylsulfonamides were also potent and irreversible inhibitors, but vinylsulfones and vinylsulfines were reversible and only poorly active. Two compounds were evaluated against A431, H125, and MCF-7 xenografts in nude mice but were inferior in these assays to the clinical trial compound CI-1033.

  DOI：

  10.1021/jm000372i

文献信息

• Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-<i>d</i>]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor
  作者：Jeff B. Smaill、H. D. Hollis Showalter、Hairong Zhou、Alexander J. Bridges、Dennis J. McNamara、David W. Fry、James M. Nelson、Veronika Sherwood、Patrick W. Vincent、Bill J. Roberts、William L. Elliott、William A. Denny

  DOI：10.1021/jm000372i

  日期：2001.2.1

  4-Anilinoquinazoline- and 4-anilinopyrido[3,4-d]pyrimidine-6-acrylamides are potent pan-erbB tyrosine kinase inactivators, and one example (CI-1033) is in clinical trial. A series of analogues with a variety of Michael acceptor units at the 6-position were prepared to define the structural requirements for irreversible inhibition. A particular goal was to determine whether additional functions to increase solubility could be appended to the Michael acceptor. Substituted acrylamides were prepared by direct acylation of the corresponding 6-amines with the requisite acid or acid chloride. Vinylsulfonamide derivatives were obtained by acylation of the amines with chloroethylsulfonyl chloride followed by base-promoted elimination. Vinylsulfone and vinylsulfine derivatives were prepared by oxidation and base elimination of a hydroxyethylthio intermediate. The compounds were evaluated for their inhibition of phosphorylation of the isolated EGFR enzyme and for inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells and of heregulin-stimulated autophosphorylation of erbB2 in MDA-MB 453 cells. Substitution at the nitrogen of the acrylamide was tolerated only with a methyl group; larger substituents were dystherapeutic, and no substitution at all was tolerated at the acrylamide ex-carbon. In contrast, while electron-donating groups at the acrylamide P-carbon were not useful, even quite large electron-withdrawing groups (which increase its electrophilicity) were tolerated. A series of derivatives with solubility-enhancing substituents linked to the acrylamide P-carbon via amides were potent irreversible inhibitors of isolated EGFR (IC(50)s = 0.4-1.1 nM), with weakly basic morpholine and imidazole derivatives being the best. Vinylsulfonamides were also potent and irreversible inhibitors, but vinylsulfones and vinylsulfines were reversible and only poorly active. Two compounds were evaluated against A431, H125, and MCF-7 xenografts in nude mice but were inferior in these assays to the clinical trial compound CI-1033.
• Irreversible inhibitors of tyrosine kinases
  申请人：Warner-Lambert Company

  公开号：US06344459B1

  公开（公告）日：2002-02-05

  The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.

  本发明提供了一种不可逆抑制酪氨酸激酶的化合物。还提供了一种治疗癌症、再狭窄、动脉粥样硬化、子宫内膜异位症和牛皮癣的方法，以及包含一种不可逆抑制酪氨酸激酶的化合物的药物组合物。